Abstract
Genetic variants in the granulin (GRN) gene have been shown to increase the risk of Alzheimer's disease (AD). Here, we report that the A allele of rs5848 in GRN reduces plasma granulin levels in a dose-dependent manner in a clinically-defined AD sample cohort. Similarly, the mRNA levels of granulin were decreased with respect to A allele of rs5848 in the inferior temporal cortex of neuropathologically confirmed AD patients. Our findings suggest that the A allele of rs5848 is functionally relevant by reducing the expression of granulin.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / blood*
-
Alzheimer Disease / genetics*
-
Alzheimer Disease / metabolism
-
Biomarkers / blood
-
Biomarkers / metabolism
-
Brain / blood supply
-
Brain / metabolism*
-
Brain / pathology*
-
Cohort Studies
-
Down-Regulation / genetics*
-
Female
-
Gene Expression Regulation
-
Genetic Variation / genetics*
-
Humans
-
Intercellular Signaling Peptides and Proteins / biosynthesis
-
Intercellular Signaling Peptides and Proteins / blood*
-
Intercellular Signaling Peptides and Proteins / genetics*
-
Male
-
Middle Aged
-
Oxidation-Reduction
-
Progranulins
Substances
-
Biomarkers
-
GRN protein, human
-
Intercellular Signaling Peptides and Proteins
-
Progranulins